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Introduction {#ehf212691-sec-0004}
============

Heart failure (HF) is a growing epidemic that affects nearly 5.7 million US adults, and the projected number of HF patients is 8.0 million in 2030.[^1^](#ehf212691-bib-0001){ref-type="ref"} Although survival after the onset of HF in adults has improved because of the development of various medications and device therapy, the overall 1 year HF mortality still remains high at approximately 30%.[^1^](#ehf212691-bib-0001){ref-type="ref"} These observations highlight the need for the identification of novel risk factors that may be amenable to intervention and for the early detection of individuals at higher risk for HF. Previous studies reported higher serum uric acid (SUA) levels in patients with HF[^2^](#ehf212691-bib-0002){ref-type="ref"}, [^3^](#ehf212691-bib-0003){ref-type="ref"} and suggested that SUA could serve as a marker for unfavourable prognosis.[^4^](#ehf212691-bib-0004){ref-type="ref"}, [^5^](#ehf212691-bib-0005){ref-type="ref"}, [^6^](#ehf212691-bib-0006){ref-type="ref"}, [^7^](#ehf212691-bib-0007){ref-type="ref"}, [^8^](#ehf212691-bib-0008){ref-type="ref"} The aetiology of elevated SUA in HF is likely multifactorial, including increased xanthine oxidase activity related to oxidative stress and inflammation and renal dysfunction because of hypoperfusion.[^2^](#ehf212691-bib-0002){ref-type="ref"}, [^3^](#ehf212691-bib-0003){ref-type="ref"}, [^9^](#ehf212691-bib-0009){ref-type="ref"} In recent years, several studies also reported the predictive value of SUA level for incident HF in some clinical settings,[^10^](#ehf212691-bib-0010){ref-type="ref"}, [^11^](#ehf212691-bib-0011){ref-type="ref"}, [^12^](#ehf212691-bib-0012){ref-type="ref"}, [^13^](#ehf212691-bib-0013){ref-type="ref"} suggesting that increase in SUA may in fact predict the onset of HF.

Left ventricular global longitudinal strain (LVGLS) is an echocardiographic measure of LV myocytes deformation, which can unmask subclinical abnormality in LV systolic function, even when LV ejection fraction (EF) is in the normal range.[^14^](#ehf212691-bib-0014){ref-type="ref"}, [^15^](#ehf212691-bib-0015){ref-type="ref"} LVGLS has prognostic value for cardiovascular events including HF and mortality, which is independent and additive to that of LVEF.[^16^](#ehf212691-bib-0016){ref-type="ref"}, [^17^](#ehf212691-bib-0017){ref-type="ref"}, [^18^](#ehf212691-bib-0018){ref-type="ref"}, [^19^](#ehf212691-bib-0019){ref-type="ref"}, [^20^](#ehf212691-bib-0020){ref-type="ref"} However, there was no study investigating the independent effect of SUA on subclinical LV dysfunction in the general population with normal LVEF. Understanding the association between SUA and subclinical LV dysfunction might provide insight into the pathogenesis linking elevated SUA and incident HF and may help inform the possible preventive strategies for HF. The aim of the present study was to investigate whether elevated SUA concentration is associated with impaired LVGLS in a community‐based cohort without overt cardiac disease.

Methods {#ehf212691-sec-0005}
=======

Study population {#ehf212691-sec-0006}
----------------

The study population was derived from the Subclinical Cardiac Dysfunction in General Population (SCADGP) study. This study was designed to assess the prevalence and determinants of subclinical cardiac dysfunction in a community‐based cohort, who underwent an extensive cardiovascular health check from August 2014 to May 2018 in the University of Tokyo. Among the 1243 participants enrolled in the SCADGP study, participants who met the following criteria were excluded: history of atrial fibrillation or atrial flutter (*n* = 15), history of coronary artery disease (*n* = 29), decreased LV systolic fraction (LVEF \< 50%) or significant valvular disease (*n* = 17), and suboptimal image quality or incomplete assessment of the echocardiographic parameters (*n* = 7). Thus, the final study group consisted of 1175 participants without overt cardiac disease. Written informed consent was obtained from all study participants. The study was approved by the Institutional Review Boards of the University of Tokyo.

Risk factor assessment and laboratory examination {#ehf212691-sec-0007}
-------------------------------------------------

Cardiovascular risk factors were ascertained through interviews and direct examination by research assistants. Hypertension was defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or the use of antihypertensive medication.[^1^](#ehf212691-bib-0001){ref-type="ref"} Diabetes mellitus was defined by the current use of insulin or hypoglycemic agents or a fasting glucose of ≥126 mg/dL.[^1^](#ehf212691-bib-0001){ref-type="ref"} Hypercholesterolemia was defined as total serum cholesterol \>240 mg/dL, or the use of lipid‐lowering medications.[^1^](#ehf212691-bib-0001){ref-type="ref"} Body mass index (BMI) was calculated using height and weight (kg/m^2^).

Venous blood samples were drawn in the fasting condition on the same day as the echocardiographic examination. The SUA level was determined using a validated enzymatic method (UA‐CL, Serotec, Chiba, Japan). Fasting blood glucose, high‐density lipoprotein (HDL) cholesterol, low‐density lipoprotein cholesterol, estimated glomerular filtration rate (eGFR), C‐reactive protein (CRP), and B‐type natriuretic peptide were also analysed in all participants.

Echocardiographic examination {#ehf212691-sec-0008}
-----------------------------

### Two‐dimensional echocardiography {#ehf212691-sec-0009}

Echocardiographic examination was performed using a commercially available system (Aplio 300, Toshiba Medical Systems, Tokyo, Japan) in accordance with a standardized protocol by trained sonographers blinded to the participant\'s clinical information. The dimensions of the cardiac chambers were measured in the standard manner.[^21^](#ehf212691-bib-0021){ref-type="ref"} LV mass was calculated with a validated formula[^22^](#ehf212691-bib-0022){ref-type="ref"}: LV mass = 0.8{1.04\[(SWT + LVEDD + PWT)^3^−LVEDD^3^\]} + 0.6, where SWT is the LV end‐diastolic septal wall thickness, LVEDD is the LV end‐diastolic diameter, and PWT is the LV end‐diastolic posterior wall thickness. Left atrial volume was measured from the apical two‐chamber and four‐chamber views using the biplane Simpson\'s rule.[^21^](#ehf212691-bib-0021){ref-type="ref"} LV mass and left atrial volume were then indexed for body surface area. LV diastolic parameters were assessed according to the current guideline.[^23^](#ehf212691-bib-0023){ref-type="ref"} Briefly, transmitral diastolic flow was obtained from an apical four‐chamber view. Pulsed‐wave Doppler examination of mitral inflow was performed to measure early (E) and late peak velocity. Peak early diastolic mitral annular velocity (e′) was also measured from tissue Doppler imaging in the lateral and the septal mitral annulus, and the average value was used. The ratio of E to mean e′ was then calculated (E/e′).

### Speckle‐tracking echocardiography {#ehf212691-sec-0010}

Speckle‐tracking analysis was performed offline using vendor‐independent commercially available software (two‐dimensional cardiac performance analysis; Tomtec Imaging System, Germany). Semi‐automated border detection was performed, and LV borders were tracked throughout the entire cardiac cycle. Manual correction was performed in case of inaccurate endocardial detection. LVGLS was calculated averaging the negative peak of longitudinal strain from all three apical views including the four‐chamber, two‐chamber, and long‐axis views, according to the current guideline.[^24^](#ehf212691-bib-0024){ref-type="ref"} Impaired LVGLS was defined as a GLS greater than −18.6%, which was the 90th percentile of the strain value distribution in the SCADGP participants without any conditions associated with LV remodelling including hypertension, diabetes mellitus, coronary artery disease, significant valvular disease, arrhythmias, or BMI \>25 kg/m^2^. Excellent correlations were observed in the inter‐observer and intra‐observer variabilities of LVGLS in 15 randomly selected participants (*r* = 0.94 and *r* = 0.95, respectively). In Bland--Altman analysis, agreement in LVGLS between the inter‐observer and intra‐observer measurements were −0.3 ± 2.1% and 0.8 ± 1.9%, respectively (mean ± 1.96 SD).

### Statistical analysis {#ehf212691-sec-0011}

Categorical variables are presented as numbers and frequencies (%) and continuous variables as means ± standard deviations. Univariable correlation between SUA level and echocardiographic parameters was evaluated by Pearson\'s correlation coefficients (*r*). Univariable and multivariable logistic regression analyses were conducted to evaluate the association of SUA level as continuous variable as well as categorical variable using quartiles with abnormal LVGLS, adjusting for significant potential cofactors (variables with *P* \< 0.1 in the univariable analysis) in the multivariable logistic regression models with stepwise fashion in five models (Model 1: adjustment for age and sex; Model 2: adjustment for age, sex, hypertension, diabetes mellitus, and BMI; Model 3: adjustment as in Model 2 plus laboratory parameters including fasting glucose, HDL cholesterol, eGFR, and CRP levels; Model 4: adjustment as in Model 3 plus echocardiographic parameters (LVEF, LV mass index, and E/e′); Model 5: adjustment as in Model 4 plus diuretics use.) and corresponding odds ratios (ORs) with their 95% confidence interval (CI) were reported. A value of *P* \< 0.05 was considered significant. All statistical analyses were performed using JMP 14 software (SAS Institute, Cary, NC, USA).

Results {#ehf212691-sec-0012}
=======

Clinical characteristics and echocardiographic data in the study population are shown in *Table* [*1*](#ehf212691-tbl-0001){ref-type="table"}. The mean age was 62 ± 12 years, and 656 (56%) were male participants. The mean value of SUA was 5.6 ± 1.3 mg/dL (25th--75th percentile, 4.6--6.5 mg/dL). The mean LVEF was 63 ± 6%, and LVGLS was −21.3 ± 2.7%.

###### 

Characteristics of the study population

  *N* = 1175                          
  ----------------------------------- -------------
  Age, years                          62 ± 12
  Male gender, *n* (%)                656 (55.8)
  Hypertension, *n* (%)               408 (34.7)
  Diabetes, *n* (%)                   120 (10.2)
  Hypercholesterolemia, *n* (%)       430 (36.6)
  Body mass index, kg/m^2^            23.5 ± 3.5
  Uric acid lowering drugs, *n* (%)   78 (6.6)
  Diuretics, *n* (%)                  35 (3.0)
  Laboratory examination              
  Glucose, mg/dL                      100 ± 19
  Total cholesterol, mg/dL            206 ± 34
  LDL cholesterol. mg/dL              125 ± 30
  HDL cholesterol, mg/dL              66 ± 19
  Uric acid, mg/dL                    5.6 ± 1.3
  eGFR, mL/min/1.73m^2^               72 ± 15
  C‐reactive protein, mg/dL           0.12 ± 0.35
  B‐type natriuretic peptide, pg/mL   23.6 ± 26.8
  Echocardiography                    
  LV end‐diastolic diameter, mm       45 ± 4
  LV end‐systolic diameter, mm        27 ± 4
  LV ejection fraction, %             63 ± 6
  LV mass index, g/m^2^               71 ± 16
  LA volume index, mL/m^2^            25 ± 7
  E wave, cm/sec                      70 ± 15
  A wave, cm/sec                      68 ± 20
  e′, cm/sec                          8.2 ± 2.3
  E/e′                                9.06 ± 2.80
  LVGLS, %                            −21.3 ± 2.7

Values are mean ± standard deviation or *n* (percentage). A, late diastolic transmitral flow velocity; E, early diastolic transmitral flow velocity; e′, early diastolic mitral annular velocity; eGFR, estimated glomerular filtration rate; GLS, global longitudinal strain; HDL, high‐density lipoprotein; LA, left atrium; LDL, low‐density lipoprotein; LV, left ventricle.

Serum uric acid was significantly correlated with LVGLS (*r* = 0.23, *P* \< 0.001; *Figure* [*1*](#ehf212691-fig-0001){ref-type="fig"}). On the other hand, there was no correlation between SUA and E/e′ (*r* = 0.04, *P* = 0.20). The prevalence of abnormal LVGLS (greater than −18.6%) was greatest in the upper quartile of SUA (21.9%), followed by the third (14.9%), second (10.4%), and first (7.6%) quartiles (*Figure* [*2*](#ehf212691-fig-0002){ref-type="fig"}). *Table* [*2*](#ehf212691-tbl-0002){ref-type="table"} shows the univariate association of clinical, laboratory, and echocardiographic variables with abnormal LVGLS. The SUA level was associated with abnormal LVGLS in the age‐adjusted and sex‐adjusted model (*Table* [*3*](#ehf212691-tbl-0003){ref-type="table"}, Model 1). In the multivariable model adjusted for age, sex, hypertension, diabetes mellitus, and BMI, this association persisted (*Table* [*3*](#ehf212691-tbl-0003){ref-type="table"}, Model 2). With further adjustment for laboratory parameters (fasting glucose, HDL cholesterol, eGFR, and CRP levels), SUA remained significantly associated with LVGLS (*Table* [*3*](#ehf212691-tbl-0003){ref-type="table"}, Model 3). Even after adjustment for echocardiographic parameters including LVEF, LV mass index, and E/e′, SUA was still independently associated with abnormal LVGLS (*Table* [*3*](#ehf212691-tbl-0003){ref-type="table"}, Model 4), and this association persisted after adjustment for diuretics (adjusted OR, 1.26 per 1 mg/dL; *P* = 0.008; *Table* [*3*](#ehf212691-tbl-0003){ref-type="table"}, Model 5). When SUA was examined as a categorical variable in the multivariable models, the upper quartile of SUA (≥6.5 mg/dL) was independently associated with abnormal LVGLS in the fully adjusted model (adjusted OR 2.28 vs. lowest quartile; 95% CI 1.14--4.58; *P* = 0.020; *Figure* [*3*](#ehf212691-fig-0003){ref-type="fig"}, Model 5).

![Scatter plots illustrating the association between SUA and LVGLS. LVGLS, left ventricular global longitudinal strain; SUA, serum uric acid.](EHF2-7-1031-g001){#ehf212691-fig-0001}

![Prevalence of abnormal GLS according to the serum uric acid level. GLS, global longitudinal strain.](EHF2-7-1031-g002){#ehf212691-fig-0002}

###### 

Univariable logistic regression analysis for abnormal LVGLS

                                  Odds ratio (95% CI)   *P* value
  ------------------------------- --------------------- -----------
  Age, years                      1.02 (1.007--1.04)    0.004
  Sex, male                       2.02 (1.42--2.90)     \<0.001
  Hypertension                    1.90 (1.36--2.65)     \<0.001
  Diabetes mellitus               1.55 (0.93--2.48)     0.089
  Hypercholesterolemia            0.92 (0.65--1.30)     0.641
  Body mass index, kg/m^2^        1.10 (1.05--1.15)     \<0.001
  Uric acid lowering drugs        1.53 (0.82--2.68)     0.175
  Diuretics                       2.58 (1.22--5.48)     0.022
  Glucose, mg/dL                  1.01 (1.001--1.02)    0.022
  Total cholesterol, mg/dL        1.00 (0.99--1.002)    0.249
  LDL cholesterol, mg/dL          1.00 (0.99--1.004)    0.604
  HDL cholesterol, mg/dL          0.98 (0.97--0.99)     \<0.001
  Uric acid, mg/dL                1.43 (1.26--1.63)     \<0.001
  eGFR, mL/min/1.73m^2^           0.98 (0.97--0.99)     0.002
  Log C‐reactive protein, mg/dL   1.61 (1.12--2.28)     0.008
  LV end‐diastolic diameter, mm   1.03 (0.995--1.07)    0.088
  LV end‐systolic diameter, mm    1.09 (1.05--1.14)     \<0.001
  LV ejection fraction, %         0.80 (0.76--0.83)     \<0.001
  LV mass index, g/m^2^           1.03 (1.02--1.04)     \<0.001
  LA volume index, mL/m^2^        1.00 (0.97--1.02)     0.771
  E/e′                            1.09 (1.04--1.15)     0.002

CI, confidence interval; E, early diastolic transmitral flow velocity, e′, early diastolic mitral annular velocity; eGFR, estimated glomerular filtration rate; GLS, global longitudinal strain; HDL, high‐density lipoprotein; LA, left atrium; LDL, low‐density lipoprotein; LV, left ventricle.

###### 

Association of SUA level with abnormal LVGLS

                     Model 1        Model 2        Model 3        Model 4        Model 5                                                               
  ------------ ------------------- --------- ------------------- --------- ------------------- ------- ------------------- ------- ------------------- -------
  SUA, mg/dL    1.39 (1.20--1.61)   \<0.001   1.32 (1.14--1.54)   \<0.001   1.29 (1.10--1.51)   0.002   1.26 (1.06--1.49)   0.009   1.26 (1.06--1.50)   0.008

CI, confidence interval; CRP, C‐reactive protein; E, early diastolic transmitral flow velocity; e′, early diastolic mitral annular velocity; eGFR, estimated glomerular filtration rate; GLS, global longitudinal strain; HDL, high‐density lipoprotein; LV, left ventricle; SUA, serum uric acid.

Model 1: age and sex adjusted.

Model 2: adjusted for age, sex, hypertension, diabetes mellitus, and body mass index.

Model 3: adjusted for variables as in Model 2 and fasting glucose, HDL cholesterol, eGFR, and CRP.

Model 4: adjusted for variables as in Model 3 and LV ejection fraction, LV mass index, and E/e′.

Model 5: adjusted for variables as in Model 4 and diuretics use.

![Association of SUA quartiles with abnormal LVGLS.Reference: Quartile 1. Multivariable Model 1: adjusted for age and sex. Multivariable Model 2: adjusted for age, sex, hypertension, diabetes mellitus and BMI. Multivariable Model 3: adjusted as in Model 2 with further adjustment for laboratory parameters including fasting glucose, HDL cholesterol, eGFR and CRP. Multivariable Model 4: adjusted as in Model 3 with further adjustment for LV ejection fraction, LV mass index, and E/e′. Multivariable Model 5: adjusted as in Model 4 with further adjustment for diuretics use. BMI, body mass index; CI, confidence interval; CRP, C‐reactive protein; E, early diastolic transmitral flow velocity; e′, early diastolic mitral annular velocity; eGFR, estimated glomerular filtration rate; GLS, global longitudinal strain; HDL, high‐density lipoprotein; LV, left ventricle; SUA, serum uric acid.](EHF2-7-1031-g003){#ehf212691-fig-0003}

Finally, in a sensitivity analysis performed in participants without treatment with SUA lowering drugs (*N* = 1097), the results of the fully adjusted models were concordant with those of the general analysis, with SUA levels remaining an independent predictor of abnormal LVGLS (adjusted OR, 1.25 per 1 mg/dL; 95% CI, 1.04--1.50; *P* = 0.015).

Discussion {#ehf212691-sec-0013}
==========

We demonstrated that an elevated SUA level was associated with impaired LVGLS in a sample of the general population without overt cardiac disease. The association was independent of traditional cardiovascular risk factors as well as pertinent laboratory and echocardiographic parameters.

Previous studies demonstrated that an elevated SUA level had prognostic value in patients with chronic as well as acute HF of varying severity.[^4^](#ehf212691-bib-0004){ref-type="ref"}, [^5^](#ehf212691-bib-0005){ref-type="ref"}, [^6^](#ehf212691-bib-0006){ref-type="ref"}, [^7^](#ehf212691-bib-0007){ref-type="ref"}, [^8^](#ehf212691-bib-0008){ref-type="ref"} Anker et al. showed that a high SUA level predicted poorer outcomes (mortality and the need for transplant) in 112 patients with moderate or severe chronic HF.[^4^](#ehf212691-bib-0004){ref-type="ref"} Pascual‐Figal et al. identified the SUA level as a strong predictor of death and HF hospital readmission in 212 acute HF patients with LVEF \<40%.[^5^](#ehf212691-bib-0005){ref-type="ref"} Wu et al. also demonstrated that a higher quartile of SUA was independently associated with mortality in 1152 severe HF patients with LVEF \<30% during a median follow‐up of 404 days.[^6^](#ehf212691-bib-0006){ref-type="ref"} A similar result was observed in HF patients with preserved LVEF.[^8^](#ehf212691-bib-0008){ref-type="ref"} The pathogenesis of elevated SUA in the setting of HF is likely multifactorial, involving impaired renal function as well as inflammatory cytokine activation and abnormalities in oxidative metabolism,[^2^](#ehf212691-bib-0002){ref-type="ref"}, [^3^](#ehf212691-bib-0003){ref-type="ref"}, [^9^](#ehf212691-bib-0009){ref-type="ref"} although the precise nature of the link between SUA and prognosis in HF is still uncertain. Current studies demonstrated that the SUA level is associated with incident HF in some clinical settings.[^10^](#ehf212691-bib-0010){ref-type="ref"}, [^11^](#ehf212691-bib-0011){ref-type="ref"}, [^12^](#ehf212691-bib-0012){ref-type="ref"}, [^13^](#ehf212691-bib-0013){ref-type="ref"} Krishnan et al. showed that subjects with SUA \>6.3 mg/dL had a 2.1‐fold higher risk of incident HF compared with those with SUA \<3.4 mg/dL in 4912 individuals from the Framingham Offspring cohort.[^11^](#ehf212691-bib-0011){ref-type="ref"} Holmes et al. demonstrated that SUA was an independent predictor of HF development in 417 734 Swedish individuals who underwent health check‐ups in outpatient clinics.[^10^](#ehf212691-bib-0010){ref-type="ref"} Kaya et al. identified hyperuricemia as an independent predictor for new‐onset HF in 2249 patients with myocardial infarction.[^13^](#ehf212691-bib-0013){ref-type="ref"} Our results are in agreement with these clinical studies and extend their findings to the subclinical LV dysfunction domain.

The quantification of myocardial systolic strain as an index of LV function is now feasible with speckle‐tracking echocardiography.[^25^](#ehf212691-bib-0025){ref-type="ref"}, [^26^](#ehf212691-bib-0026){ref-type="ref"} GLS, a measure of the myocardial systolic deformation over the longitudinal axis, is emerging as an important tool to detect early LV dysfunction and is more sensitive than LVEF.[^14^](#ehf212691-bib-0014){ref-type="ref"}, [^15^](#ehf212691-bib-0015){ref-type="ref"} Moreover, an impaired GLS is associated with unfavourable cardiovascular outcomes including HF independent of LVEF.[^16^](#ehf212691-bib-0016){ref-type="ref"}, [^17^](#ehf212691-bib-0017){ref-type="ref"}, [^18^](#ehf212691-bib-0018){ref-type="ref"}, [^19^](#ehf212691-bib-0019){ref-type="ref"}, [^20^](#ehf212691-bib-0020){ref-type="ref"} We demonstrate for the first time that an elevated SUA level was associated with impaired GLS in a general population with normal LVEF, independent of traditional cardiovascular risk factors, pertinent laboratory parameters including serum CRP levels and eGFR, and LV morphology and diastolic function. Upper quartile of SUA (≥6.5 mg/dL) carries approximately two‐fold increased risk of abnormal LVGLS. Our findings suggest that SUA may act as a surrogate marker of subclinical LV dysfunction, although the possibility that it may play a mechanistic role in its development cannot be excluded on these data. Furthermore, the relationship between elevated SUA and impaired LVGLS may be involved in explaining the increased HF risk in individuals with high SUA level. The underlying mechanisms of this association are not entirely clear, but we hypothesize several potential explanations. First, SUA is an index of oxidative stress that could be involved in ventricular remodelling, affecting inotropic and/or lusitropic function, and elevated SUA could potentially lead to myocardial fibrosis.[^9^](#ehf212691-bib-0009){ref-type="ref"}, [^27^](#ehf212691-bib-0027){ref-type="ref"} Second, SUA contributes to endothelial dysfunction via impairing nitric oxide production and subsequent vasoconstriction and altered myocyte and endothelial cell guanosine monophosphate cyclase resulting in increased cardiovascular rest tension and extracellular matrix deposition.[^28^](#ehf212691-bib-0028){ref-type="ref"}, [^29^](#ehf212691-bib-0029){ref-type="ref"} Third, elevated SUA may induce a chronic inflammatory state leading to worsened LV function.[^3^](#ehf212691-bib-0003){ref-type="ref"} Finally, elevated SUA may impair the coronary microcirculation resulting in LV dysfunction.[^30^](#ehf212691-bib-0030){ref-type="ref"} Although a high SUA level might be an epiphenomenon and just serve as a marker of reduced excretion because of renal dysfunction, which may reduce LV contractility, we demonstrated a significant association between SUA levels and LVGLS independent of renal function. Previous studies demonstrated the association between SUA and diastolic parameters in patients with established cardiac disease including HF and cardiomyopathy,[^31^](#ehf212691-bib-0031){ref-type="ref"}, [^32^](#ehf212691-bib-0032){ref-type="ref"}, [^33^](#ehf212691-bib-0033){ref-type="ref"} whereas SUA was not correlated with E/e′ in the present study. This discrepancy might be partially explained by the difference in study population, namely, we included individuals without overt cardiac disease who had relatively preserved diastolic function.

While our observations raise the possibility of HF prevention in individuals with elevated SUA levels, conflicting results were obtained on the effects of therapeutic interventions to reduce SUA. Oxypurinol reduced SUA without any clinical benefits in 405 symptomatic HF patients, although a *post hoc* analysis suggested possible benefits in patients with SUA \>9.5 mg/dL.[^34^](#ehf212691-bib-0034){ref-type="ref"} Furthermore, Givertz et al. found that allopurinol failed to improve clinical status as well as LVEF at 24 weeks in 253 symptomatic HF patients with LVEF ≤40% and SUA ≥9.5 mg/dL.[^35^](#ehf212691-bib-0035){ref-type="ref"} On the other hand, a recent multicentre, prospective, randomized open‐label study demonstrated the beneficial effect of xanthine oxidase inhibitors on cardiovascular outcomes in 1070 hyperuricaemic subjects.[^36^](#ehf212691-bib-0036){ref-type="ref"} These conflicting results might be partially explained by the difference in study population, namely, xanthine oxidase inhibitor might be useful in individuals free of HF but not in the setting of established HF. Future studies are warranted to assess whether therapeutic strategies aimed at lowering SUA levels may improve subclinical LV dysfunction and prevent or delay the development of HF. Furthermore, although we demonstrated the association between SUA and subclinical LV dysfunction, future studies are needed to explore the pathophysiological mechanisms linking SUA and subclinical LV dysfunction, which might provide valuable information regarding the possible preventive therapeutic strategies for LV dysfunction and subsequent HF development in individuals with elevated SUA.

Study limitations {#ehf212691-sec-0014}
-----------------

Because of the cross‐sectional nature of our study, we could not confirm a cause--effect relationship between SUA and subclinical LV dysfunction or estimate the impact of SUA on HF development. Although some previous studies demonstrated the association between SUA and the extent of coronary atherosclerosis,[^37^](#ehf212691-bib-0037){ref-type="ref"} we cannot clearly ascertain the absence of obstructive coronary artery disease. In addition, the impact of differences in diet on our observations could not be assessed, because complete information of diet was not uniformly available in our study. These factors might affect our observations about the independent association between SUA and subclinical LV dysfunction.

Conclusions {#ehf212691-sec-0015}
===========

This study demonstrated a significant association between elevated SUA and impaired LVGLS in a sample of the general population without overt cardiac disease. This finding may be important in explaining the underlying pathophysiological mechanism for the higher incidence of HF in individuals with elevated SUA. In addition, the assessment of LVGLS may add important information in the prognostic assessment of individuals with elevated SUA, even in the absence of overt cardiac disease.
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